ICYMI: Positive Topline Data Available on Vimseltinib for TGCT
Surgical resection remains the most common treatment approach for people living with tenosynovial giant cell tumors (TGCT). Unfortunately, surgery is not always an appropriate
GCT Support
GCT Support
Giant Cell Tumor (GCT) of the bone is a type of rare, locally aggressive, tumor that typically impacts the ends of long bones. GCT of the bone represents 5% of all bone tumors and 20% of all benign bone tumors.
GCT Support is a community open to GCT patients, their caregivers and family members. It is also open to physicians, researchers, and others interested in learning more about GCT and helping those with the disease. Joining the community is free! We want to come together to share medical experiences, provide each other with support, and share tools to guide you through your GCT journey. Most importantly, we are here to ensure that no one faces GCT alone. If you have any questions or need more information, please feel free to contact us at [email protected]
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
- Giant Cell Tumor of the Bone (GCT)
Resources & Support
Patient Worthy Posts on GCT
Rare Classroom: Tenosynovial Giant Cell Tumor
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on
Making History: First Treatment for TGCT Gets FDA Approved
According to a story from fda.gov, the US Food and Drug Administration (FDA) has approved the drug pexidartinib (marketed as Turalio) as a treatment for
Positive Data from Phase 3 Trial for Potential TGCT Treatment
According to a story from BioSpace, the drug developer Daiichi Sankyo Company Limited has recently announced positive data resulting from a pooled anaylsis of a
